Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules

摘要

ObjectivePatients who have incidentally detected pulmonary nodules and an estimated intermediate risk (5–60%) of lung cancer frequently are followed via computed tomography (CT) surveillance to detect nodule growth, despite guidelines for a more aggressive diagnostic strategy. We examined the cost-effectiveness of an autoantibody test (AABT)—Early Cancer Detection Test-Lung (EarlyCDT-Lung^TM)—as an aid to early diagnosis of lung cancer among such patients.